MedPath

Prospective clinical study on efficacy and tolerability (examination of gastrointestinal symptoms) of mineral and bone disorder of Sucroferric oxyhydroxide in hemodialysis patients

Not Applicable
Conditions
Hyperphosphatemia in chronic kidney disease patients on hemodialysis
Registration Number
JPRN-UMIN000033634
Lead Sponsor
kitasao University, School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
10
Inclusion Criteria

Not provided

Exclusion Criteria

Patients who conflict with one of the following are excluded from this study. 1)Patients who have a history of hypersensitivity to the ingredients of sucroferric oxyhydroxide 2)Patients falling under the careful administration of sucroferric oxyhydroxide 3)Patients taking phosphorus binder drugs other than precipitated calcium carbonate 4)Patients taking Lubiprostone 5)Patients receiving antibiotics 6)patients who judged that the doctor in charge is not appropriate

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
the change of serum phosphorus concentration, corrected calcium concentration, serum intact-PTH concentration at the start and after 3 months
Secondary Outcome Measures
NameTimeMethod
1)State of occurrence of side effects 2)Clinical examination (iron related examination) 3)Defecation status 4)Medication status
© Copyright 2025. All Rights Reserved by MedPath